Moving Advisory Boards Online: Is an Asynchronous Platform the Answer?

Natalie DeMasi, clinical development and medical affairs researcher
By Natalie DeMasi,
Senior Research Analyst

Nowadays, everything is going online — shopping, education courses, movie-watching — and the life sciences is no different.  Whether it’s product marketing or patient advocacy, pharma companies are figuring out how to best use digital technology to reach their target audiences and (maybe) save a little money along the way.  Advisory boards are no exception. Continue reading


Female Key Opinion Leaders Receive Smaller Percentage of Research Funding, Finds Recent Cleveland Clinic Study

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Over the past few years, the industry has paid close attention to the Sunshine Act’s physician payment reporting requirements.  Ideally, publication of payment data will usher in a new era of transparency regarding how key opinion leaders (KOLs) interact with life science teams.  However, while many healthcare consumers may welcome Sunshine Act reporting, some physicians and industry groups remain apprehensive that consumers will take financial information out of context.  Moreover, previously released physician payment data already demonstrates that individuals may not always receive equivalent compensation for the same types of work. Continue reading


Medical Device Brands: New Products Face Heavy Competition in the US Market

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

It’s no secret that the life sciences commercial landscape is saturated with established brands, and that more products enter the market each year.  Companies must have a strong understanding of their major competitors early in product development as they prepare for launch.  However, medical device brands are very different even from their closest competitors.  As such, companies can expect their products to enter markets with varying degrees of commercial competition.  While some therapeutic areas are more competitive than others, product novelty is also a determining factor as new product planning and commercial executives prepare for launch. Continue reading



Balancing HEOR Team Priorities Between Short Term Approval Goals and Long Term Market Access Strategy

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

For many pharmaceutical companies, HEOR is a non-stop endeavor. Working to support existing products — while also developing value dossiers for products that are about to launch — can put a strain on available resources.  To a certain extent, the specifics of an HEOR team’s workload is dictated by market needs and external pressures.  But there are steps that can be taken internally to ensure that quality HEOR work is delivered on a consistent basis. Continue reading



Something to Talk About: Gathering the Patient Voice to Inform Customer-Centric Marketing Strategies

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Today, patients are more involved in their own healthcare decisions than ever before.  While pharmaceutical firms shift their commercial targets to include payer and government systems, marketing and sales teams also benefit by reaching out to their end-users.  Thanks to the abundance of information available on the Internet, as well as a number of health-focused mobile applications, patients are able to more actively engage with doctors and influence treatment plans.  To accommodate these more active consumers, companies should look to patient-centric marketing strategies as an integral part of their commercial mix. Continue reading



Pharmaceutical KOL Disclosure Requirements: Global Transparency Trends

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Often, life science companies elect to partner with industry experts or pharmaceutical KOLs to support their medical affairs activities.  However, companies may struggle to determine the appropriate physician fair market value (FMV) rates to provide these external experts.  For industry teams in the US, the knowledge that physician remuneration will become public knowledge — in-line with Sunshine Act reporting requirements — contributes to this perceived challenge.  Continue reading


Medical Device Development: Looking to External Resources to Drive Product Management

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Life sciences firms consume a lot of resources — both budgets and time — on medical device development and commercializing their brands.  While many companies prefer to keep development in-house, others look to outside resources to supplement internal capabilities or to bolster their portfolios. For many companies, collaboration or acquisitions are viable options to move medical devices to market. Continue reading